|
🐜
|
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
17 auth.
T. Crosby,
C. Hurt,
S. Falk,
S. Gollins,
S. Mukherjee,
J. Staffurth,
J. Staffurth,
Ruby Ray,
N. Bashir,
J. Bridgewater,
...
J. Geh,
D. Cunningham,
J. Blazeby,
R. Roy,
T. Maughan,
G. Griffiths,
G. Griffiths
|
8 |
2013 |
8
🐜
|
|
🐜
|
Proteomics Analysis of Bladder Cancer Exosomes*
8 auth.
Joanne L Welton,
S. Khanna,
P. Giles,
P. Brennan,
I. Brewis,
J. Staffurth,
...
M. Mason,
A. Clayton
|
8 |
2010 |
8
🐜
|
|
🐜
|
Can urinary exosomes act as treatment response markers in prostate cancer?
7 auth.
Paul J Mitchell,
Joanne L Welton,
J. Staffurth,
J. Court,
M. Mason,
Z. Tabi,
...
A. Clayton
|
8 |
2009 |
8
🐜
|
|
🐜
|
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
30 auth.
F. Hamdy,
J. Donovan,
J. Lane,
C. Metcalfe,
M. Davis,
E. Turner,
R. M. Martin,
G. Young,
E. Walsh,
R. Bryant,
P. Bollina,
A. Doble,
A. Doherty,
D. Gillatt,
V. Gnanapragasam,
...
O. Hughes,
R. Kockelbergh,
H. Kynaston,
A. Paul,
E. Páez,
P. Powell,
D. Rosario,
E. Rowe,
M. Mason,
J. Catto,
Tim J. Peters,
J. Oxley,
Naomi J. Williams,
J. Staffurth,
D. Neal
|
8 |
2023 |
8
🐜
|
|
🐜
|
Clinical development of new drug–radiotherapy combinations
39 auth.
Ricky A. Sharma,
R. Plummer,
J. Stock,
T. Greenhalgh,
O. Ataman,
S. Kelly,
R. Clay,
R. Adams,
R. Baird,
L. Billingham,
Sarah R Brown,
Sean W. Buckland,
Helen Bulbeck,
A. Chalmers,
G. Clack,
...
A. Cranston,
L. Damstrup,
R. Ferraldeschi,
M. Forster,
J. Golec,
R. Hagan,
E. Hall,
A. Hanauske,
K. Harrington,
T. Haswell,
M. Hawkins,
T. Illidge,
Hazel Jones,
A. Kennedy,
F. McDonald,
T. Melcher,
J. O’Connor,
Jack Pollard,
M. Saunders,
D. Sebag‐Montefiore,
M. Smitt,
J. Staffurth,
I. Stratford,
S. Wedge
|
8 |
2016 |
8
🐜
|
|
🦁
|
A review of the clinical evidence for intensity-modulated radiotherapy.
J. Staffurth
|
7 |
2010 |
7
🦁
|
|
🐜
|
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
10 auth.
S. Nilsson,
P. Strang,
A. Aksnes,
L. Franzén,
P. Olivier,
A. Pecking,
...
J. Staffurth,
S. Vasanthan,
C. Andersson,
Ø. Bruland
|
7 |
2012 |
7
🐜
|
|
🐬
|
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.
M. Shelley,
S. Kumar,
T. Wilt,
J. Staffurth,
B. Coles,
M. Mason
|
7 |
2009 |
7
🐬
|
|
🐜
|
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
22 auth.
N. James,
S. Pirrie,
A. Pope,
D. Barton,
L. Andronis,
Ilias Goranitis,
S. Collins,
A. Daunton,
D. McLaren,
J. O’Sullivan,
...
C. Parker,
E. Porfiri,
J. Staffurth,
A. Stanley,
J. Wylie,
S. Beesley,
A. Birtle,
Janet E Brown,
P. Chakraborti,
S. Hussain,
M. Russell,
L. Billingham
|
6 |
2016 |
6
🐜
|
|
🐜
|
Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer
14 auth.
T. Crosby,
C. Hurt,
S. Falk,
S. Gollins,
J. Staffurth,
Ruby Ray,
J. Bridgewater,
J. Geh,
D. Cunningham,
J. Blazeby,
...
R. Roy,
T. Maughan,
G. Griffiths,
S. Mukherjee
|
6 |
2017 |
6
🐜
|
|
🐢
|
Clinical application of image-guided radiotherapy in bladder and prostate cancer.
M. Button,
J. Staffurth
|
5 |
2010 |
5
🐢
|
